The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
Response to Letter to the Editor from Riahi and Gruntmanis: 'Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates'
J Clin Endocrinol Metab. 2023 Mar 22:dgad161. doi: 10.1210/clinem/dgad161. Online ahead of print.NO ABSTRACTPMID:36947075 | DOI:10.1210/clinem/dgad161 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 22, 2023 Category: Endocrinology Authors: WuQiang Fan Benjamin Z Leder Marcy B Bolster Source Type: research
"Letter to the Editor from Riahi and Gruntmanis: 'Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates'
J Clin Endocrinol Metab. 2023 Mar 22:dgad162. doi: 10.1210/clinem/dgad162. Online ahead of print.NO ABSTRACTPMID:36947069 | DOI:10.1210/clinem/dgad162 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 22, 2023 Category: Endocrinology Authors: Shayan Riahi Ugis Gruntmanis Source Type: research
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools
ConclusionAn offer of 2-step screening with risk assessment and BMD measurement toselected postmenopausal females with low prevalence of prior fracture probably results in a small reduction in the risk of clinical fragility fracture and hip fracture compared to no screening. These findings were most applicable to the use of clinical FRAX for risk assessment and were not replicated in theoffer-to-screen population where the rate of response to mailed screening questionnaires was low. Limited direct evidence on harms of screening were available; using study data to provide estimates, there may be a moderate degree of overdia...
Source: Systematic Reviews - March 21, 2023 Category: International Medicine & Public Health Source Type: research
Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma
IntroductionMalignant pleural mesothelioma (MPM) is a rare and highly aggressive thoracic tumor with poor prognosis and limited therapeutic options. Although immune checkpoint inhibitors exhibit a promising effect in some patients with unresectable MPM in clinical trials, the majority of MPM patients show only modest response rates to the currently available treatments. It is thus imperative to develop novel and innovative therapeutic modalities for MPM, including immune effector cell-based therapies.Methodsγδ T cells were expanded using tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino) ethylidene-1,1-bisphosphonate (PTA...
Source: Frontiers in Immunology - March 17, 2023 Category: Allergy & Immunology Source Type: research
A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome
Clinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients. Human osteoclasts ex vivo reportedly displayed a variable sensitivity t... (Source: Clinical Epigenetics)
Source: Clinical Epigenetics - March 13, 2023 Category: Research Authors: Qihua Tan, Ana ïs Marie Julie Møller, Chuan Qiu, Jonna Skov Madsen, Hui Shen, Troels Bechmann, Jean-Marie Delaisse, Bjarne Winther Kristensen, Hong-Wen Deng, David Karasik and Kent Søe Tags: Research Source Type: research
Development of a First ‐in‐Class Unimolecular Dual GIP/GLP‐2 Analogue, GL‐0001, for the Treatment of Bone Fragility
The first-in-class unimolecular dual GIP/GLP-2 analogue GL-0001 activates both GIPr and GLP-2r, resulting in cAMP production and lysyl oxidase expression. Then lysyl oxidase increases collagen cross-linking and bone material strength. ABSTRACTDue to aging of the population, bone frailty is dramatically increasing worldwide. Although some therapeutic options exist, they do not fully protect or prevent against the occurrence of new fractures. All current drugs approved for the treatment of bone fragility target bone mass. However, bone resistance to fracture is not solely due to bone mass but relies also on bone extracellula...
Source: Journal of Bone and Mineral Research - March 10, 2023 Category: Orthopaedics Authors: Benoit Gobron,
Malory Couchot,
Nigel Irwin,
Erick Legrand,
B éatrice Bouvard,
Guillaume Mabilleau Tags: Research Article Source Type: research
Rheumatoid arthritis treatment with zoledronic acid, a potentialinhibitorofGWAS-derived pharmacogenetics STAT3 and IL2targets
Gene. 2023 Mar 6:147338. doi: 10.1016/j.gene.2023.147338. Online ahead of print.ABSTRACTRheumatoid arthritis (RA) is an inflammatory condition that primarily affects the joints and progress to affect other vital organs. Variety of drugs is being recommended to control the disease progression that benefits patients to perform day-to-day activities. Few of these RA drugs have noticeable side effects; therefore, it's crucial to choose the appropriate drug for treating RA with an understanding of the disease's pathophysiology. Herein, we investigated the RA genes from GWAS data to construct protein-protein interaction (PPI) ne...
Source: Gene - March 8, 2023 Category: Genetics & Stem Cells Authors: V Janakiraman M Sudhan Shankargouda Patil Khalid J Alzahrani Fuad M Alzahrani Ibrahim F Halawani Shiek S S J Ahmed Source Type: research
Rheumatoid arthritis treatment with zoledronic acid, a potentialinhibitorofGWAS-derived pharmacogenetics STAT3 and IL2targets
Gene. 2023 Mar 6:147338. doi: 10.1016/j.gene.2023.147338. Online ahead of print.ABSTRACTRheumatoid arthritis (RA) is an inflammatory condition that primarily affects the joints and progress to affect other vital organs. Variety of drugs is being recommended to control the disease progression that benefits patients to perform day-to-day activities. Few of these RA drugs have noticeable side effects; therefore, it's crucial to choose the appropriate drug for treating RA with an understanding of the disease's pathophysiology. Herein, we investigated the RA genes from GWAS data to construct protein-protein interaction (PPI) ne...
Source: Gene - March 8, 2023 Category: Genetics & Stem Cells Authors: V Janakiraman M Sudhan Shankargouda Patil Khalid J Alzahrani Fuad M Alzahrani Ibrahim F Halawani Shiek S S J Ahmed Source Type: research
Differences between zoledronic acid and denosumab for breast cancer treatment
AbstractZoledronic acid and denosumab are bone-modifying agents that are clinically important in multiple aspects of bone management for breast cancer patients. These aspects include the prevention of osteoporosis induced by cancer-treatment bone loss, treatment and prevention of bone metastasis, and improvement of survival directly or indirectly by maintaining bone health. Interestingly, zoledronic acid and denosumab have different anticancer activities, and they may be associated with the improvement of survival of breast cancer patients under different mechanisms. Zoledronic acid is the most potent bisphosphonate. It pr...
Source: Journal of Bone and Mineral Metabolism - March 7, 2023 Category: Orthopaedics Source Type: research
Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI
We describe a boy with severe OI type VI who was initially treated with intravenous (IV) zoledronic acid (ZA) at 1.4 years of age; however, a year later he transitioned to denosumab 1 mg/kg sub-cutaneously every three months in an effort to decrease fracture rates. After two years on denosumab, he presented with symptomatic hypercalcemia due to the denosumab-induced, hyper-resorptive rebound phenomenon. Laborat ory parameters at the time of the rebound were as follows: elevated serum ionized calcium (1.62 mmol/L,N 1.16 –1.36), elevated serum creatinine due to hypercalcemia-induced muscle catabolism (83 µmol/L,N 9 ...
Source: Calcified Tissue International - March 3, 2023 Category: Orthopaedics Source Type: research
Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance
ConclusionThis 3-year post-marketing surveillance confirmed the real-world safety and effectiveness of ZOL. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - March 2, 2023 Category: Orthopaedics Source Type: research
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
ConclusionsMM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor- κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and surv ival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with b...
Source: Journal of Bone and Mineral Metabolism - March 1, 2023 Category: Orthopaedics Source Type: research
